darunavir synoptis 600 mg tabletki powlekane
synoptis pharma sp. z o.o. - darunavirum - tabletki powlekane - 600 mg
darunavir synoptis 800 mg tabletki powlekane
synoptis pharma sp. z o.o. - darunavirum - tabletki powlekane - 800 mg
darunavir glenmark 400 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - darunavirum - tabletki powlekane - 400 mg
darunavir glenmark 600 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - darunavirum - tabletki powlekane - 600 mg
darunavir glenmark 800 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - darunavirum - tabletki powlekane - 800 mg
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - Środki przeciwnowotworowe - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
hepcludex
gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - Środki przeciwwirusowe do użytku ogólnoustrojowego - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - Środki przeciwnowotworowe - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
retsevmo
eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - Środki przeciwnowotworowe - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.